Can My GP Prescribe Semaglutide UK? Ozempic, Wegovy & Rybelsus

Before answering whether your GP can prescribe semaglutide, it is important to understand that semaglutide is marketed as three distinct products in the UK, each with different licensed indications, doses, and prescribing pathways.

Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg — subcutaneous injection): - Licensed in the UK for type 2 diabetes mellitus in adults, to improve glycaemic control alongside diet and exercise - Also licensed for cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease - This is the product most commonly prescribed off-label for weight loss

Wegovy (semaglutide 2.4 mg — subcutaneous injection): - Licensed in the UK specifically for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity - NICE TA875 recommends it for NHS use through specialist Tier 3 weight management services only - Represents the highest approved dose of semaglutide

Rybelsus (semaglutide 3 mg, 7 mg, 14 mg — oral tablets): - Licensed for type 2 diabetes mellitus in adults only - The only oral semaglutide product; bioavailability is significantly lower than injectable formulations - No weight management licence

Understanding which product applies to your situation is the first step in determining who can prescribe it.

UK NHS GPs have broad prescribing authority — they can prescribe any licensed medicine that is clinically appropriate for a patient, including off-label uses. However, practical prescribing of semaglutide is shaped by NHS guidance, local ICB policies, and clinical appropriateness — not a legal restriction on GP authority per se.

What GPs can generally prescribe:

Ozempic for type 2 diabetes: - Most NHS GPs can and do prescribe Ozempic for patients with type 2 diabetes — it is a second-line glucose-lowering agent typically initiated after or alongside metformin - NICE guidance for type 2 diabetes (NG28) supports GLP-1 receptor agonist use in primary care; Ozempic is within the routine prescribing competence of most GPs - Some ICBs have formulary guidance preferring specific agents (e.g., dulaglutide over semaglutide) for cost reasons, but GPs retain clinical discretion

Rybelsus for type 2 diabetes: - Similar situation to Ozempic — generally within GP prescribing scope for T2DM

What GPs typically cannot initiate:

Wegovy for weight management: - NICE TA875 specifies that Wegovy must be prescribed as part of a specialist weight management service — meaning GP initiation of Wegovy for weight management is outside the recommended NHS pathway - Some ICBs have shared care protocols that allow GPs to continue prescribing Wegovy after Tier 3 initiation, but initiation remains a specialist function - A GP who initiates Wegovy independently for weight loss (without specialist oversight) would be prescribing outside NICE guidance — which has clinical governance implications

Shared care is a formal arrangement in which a specialist service initiates a complex medication and then transfers prescribing responsibility to the patient's GP, with agreed monitoring and escalation protocols. It is designed to make specialist-initiated medications accessible through primary care without ongoing specialist appointments for every prescription.

How shared care works for Wegovy: 1. Patient is assessed and initiated on Wegovy in a NICE-compliant Tier 3 specialist service 2. After stabilisation (usually 3–6 months, once an effective and tolerated dose is reached), the specialist offers to transfer prescribing to the GP under a shared care agreement 3. The GP agrees to the shared care protocol (which specifies monitoring requirements, dose management, and escalation criteria) 4. The GP then issues repeat prescriptions for Wegovy — potentially making it much more convenient than returning to specialist services for each prescription

Challenges with shared care in practice (2026): - Not all ICBs have finalised Wegovy shared care protocols — the medication is relatively new to the NHS and administration takes time - Some GPs decline to participate in shared care for medications they are unfamiliar with, particularly given prescribing liability concerns - Shared care may not include dose titration — adjustments above the initial dose may still require return to specialist services - NHS supply constraints for Wegovy have occasionally disrupted shared care prescribing, forcing patients back to specialist services for supply management

Ask your specialist: If you are in a Tier 3 service and have reached a stable dose, ask your specialist team whether shared care is available in your area and when this can be arranged with your GP.

Outside the NHS pathway, private GPs and prescribers operate under different rules — they can prescribe licensed medicines according to their clinical judgement, without the constraint of NHS commissioning policies or NICE prescribing restrictions.

What private GPs can do: - Prescribe Ozempic, Wegovy or Rybelsus for their licensed indications following a clinical assessment - Prescribe Ozempic off-label for weight management in patients without type 2 diabetes — this is common practice in private weight loss clinics - Issue a private prescription that the patient takes to a UK private pharmacy for dispensing

Private prescribing routes: - Private GP clinic: face-to-face consultation with a private GP; prescribing decision based on full clinical assessment. Typically £100–£300 for an initial consultation - Online telehealth platforms (e.g., Juniper, Numan, Second Nature, Manual): GP or pharmacist prescriber reviews clinical questionnaire and medical history; issues prescription digitally. Lower cost (often £0–£50 for initial consultation, medication cost separate) - Pharmacist prescriber services: Some private pharmacies operate their own prescribing clinics

Regulatory requirements regardless of route: - The prescriber must be registered with the GMC, NMC, or GPhC and must hold prescribing authority - A clinical assessment must occur — prescribing without any patient assessment is illegal - The patient must be informed of licensed vs off-label status, and key risks and side effects

Costs to expect: - Ozempic (0.5–2 mg) on private prescription: approximately £80–£160/month depending on dose and pharmacy - Wegovy (2.4 mg): approximately £180–£250/month at maintenance dose - Consultation fees: £30–£100/month on ongoing platforms; higher for in-person private GPs

Based on the above, here is a practical guide to the most likely routes to semaglutide in the UK.

If you have type 2 diabetes: - Talk to your GP — Ozempic or Rybelsus is a standard NHS option and your GP can initiate it - If your GP is reluctant, ask for a referral to a diabetologist or GP with a special interest in diabetes - Ensure your HbA1c, weight, BMI, and cardiovascular risk factors are clearly documented

If you want Wegovy for weight management on the NHS: - Ask your GP for a Tier 3 weight management referral — be prepared to mention NICE TA875 by name - You may be asked to complete Tier 2 first; enrol immediately - Expect a significant wait (see the dedicated NHS Wegovy waiting list article)

If you want weight management treatment faster (private route): - Research CQC-registered online platforms or private weight loss clinics - Verify prescriber registration before sharing medical information or paying - Check whether they offer Mounjaro (tirzepatide) — it may be more available and has stronger average efficacy than Ozempic for weight loss - Always inform your NHS GP that you are on private GLP-1 treatment

If you are unsure of your eligibility: - Request a GP appointment to discuss your BMI, comorbidities, and medication options — GPs are the gatekeepers to both NHS and private referral and can advise on your specific situation - Take a printed summary of NICE TA875 eligibility criteria if you feel it would help the conversation

*This article is for general educational purposes. NHS prescribing policies, NICE guidance and local ICB arrangements change — always verify current information with your GP and local NHS commissioning body.*